EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome

Christof Skos, Jovan Rogozarski, Marek Postula, Ceren Eyileten, Cihan Ay, Bernd Jilma, Renate B Schnabel, Jolanta M Siller-Matula

Journal of Thrombosis and Haemostasis · 2026-04 · 24 (4) · 1469-1481

DOI: 10.1016/j.jtha.2025.11.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-04. Verfasst von Christof Skos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. Electronic address: christof.skos@meduniwi…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Factor Xa Inhibitors, Anticoagulants, Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, European Research Council, Deutsches Zentrum für Herz-Kreislaufforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Percutaneous coronary intervention (PCI) is a widely used treatment strategy for coronary artery disease. Optimal long-term antithrombotic therapy after PCI remains challenging. OBJECTIVES: This substudy of the Vienna PCI Registry assessed long-term effects of direct oral anticoagulant (DOAC) use on major adverse cardiac events (MACEs) in patients with chronic coronary syndrome (CCS) after PCI, exploring possible pleiotropic effects. METHODS: We analyzed patients with CCS from the Vienna PCI Registry treated with a drug-eluting stent (DES) between 2015 and 2020. The primary end point was clinically driven target lesion revascularization (TLR). The secondary composite end point (MACE) included TLR, target vessel revascularization (TVR), stent thrombosis (ST), and all-cause death. Patients received either triple antithrombotic therapy (TAT; DOAC, aspirin, and clopidogrel), followed by DOAC monotherapy, or dual antiplatelet therapy (DAPT; aspirin and clopidogrel), followed by single antiplatelet therapy. RESULTS: Among 1046 patients with CCS, 176 (16.8%) received TAT followed by DOAC monotherapy. The primary end point TLR occurred significantly less often in TAT-treated patients (2.8% vs 8.4%). MACE rates were similar between TAT and DAPT groups (17.0% vs 17.0%). All-cause mortality was higher in the TAT group (11.9% vs 7.8%). Multivariable regression showed that TAT followed by DOAC monotherapy was associated with a reduced 5-year risk of TLR compared with DAPT followed by single antiplatelet therapy (odds ratio, 0.367; 95% CI, 0.147-0.917; P =.032). CONCLUSION: Patients treated with TAT demonstrated a statistically significant risk decrease for the primary end point clinically driven TLR in the elective CCS-PCI setting at 5 years' follow-up, which may be in part due to pleiotropic effects of DOACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionFactor Xa InhibitorsAnticoagulantsCoronary Artery DiseaseHumansFemaleMaleAgedMiddle AgedRegistriesAdministration, OralDrug-Eluting StentsTreatment OutcomePlatelet Aggregation InhibitorsTime FactorsChronic DiseaseRisk FactorsAustria

Stichwörter der Autor:innen

anticoagulantscoronary artery diseasedrug-eluting stentspercutaneous coronary interventionplatelet aggregation inhibitors

Substanzen

Platelet Aggregation InhibitorsFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. Electronic address: christof.skos@meduniwien.ac.at.
  • Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Department of Experimental Physiology and Pathophysiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
  • Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.
  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • Horizon 2020 Framework Programme
  • European Research Council
  • Deutsches Zentrum für Herz-Kreislaufforschung
  • Deutsche Herzstiftung

Zitieren

APA

Skos, C., Rogozarski, J., Postula, M., Eyileten, C., Ay, C., Jilma, B., Schnabel, R. B., & Siller-Matula, J. M. (2026). Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome. Journal of Thrombosis and Haemostasis, 24(4), 1469-1481. https://doi.org/10.1016/j.jtha.2025.11.016

Vancouver

Skos C, Rogozarski J, Postula M, Eyileten C, Ay C, Jilma B, et al. Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome. Journal of Thrombosis and Haemostasis. 2026;24(4):1469-1481. doi:10.1016/j.jtha.2025.11.016

BibTeX
@article{Skos2026,
  author = {Skos, Christof and Rogozarski, Jovan and Postula, Marek and Eyileten, Ceren and Ay, Cihan and Jilma, Bernd and Schnabel, Renate B and Siller-Matula, Jolanta M},
  title = {Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {1469--1481},
  doi = {10.1016/j.jtha.2025.11.016}
}
Kostenlos starten →